Business Alliance on the New Radiopharmaceutical 'Metastron Injectable' (Japan)
This article was originally published in PharmAsia News
Executive Summary
Nippon Kayaku Co. is partnering with Nihon Medi-Physics. The two companies are teaming up to focus on the Japanese distribution of Metastron Injectable. A radiopharmaceutical developed by GE Healthcare, the Metastron Injectable is designed to treat pain associated with metastasized bone cancer. Under the terms of their partnership, Nippon will focus on how to best market Metastron Injectable to healthcare facilities. Nihon will then concentrate finding best practices for the injection's import and distribution as well as educating medical practitioners on its safe and effective use. (Click here for more